Study: Checkpoint inhibitor prolongs survival in patients with head and neck cancers

The checkpoint inhibitor pembrolizumab (Keytruda) offers patients with advanced head and neck cancers longer survival time, according to a new global study led by Yale Cancer Center (YCC). The data was published today in the journal The Lancet.

From http://besthealthnews.com/2019/11/study-checkpoint-inhibitor-prolongs-survival-in-patients-with-head-and-neck-cancers/?utm_source=rss&utm_medium=rss&utm_campaign=study-checkpoint-inhibitor-prolongs-survival-in-patients-with-head-and-neck-cancers

from
https://healthnews010.wordpress.com/2019/11/01/study-checkpoint-inhibitor-prolongs-survival-in-patients-with-head-and-neck-cancers/

From https://aubreyflores.blogspot.com/2019/11/study-checkpoint-inhibitor-prolongs.html

from
https://aubreyflores.wordpress.com/2019/11/01/study-checkpoint-inhibitor-prolongs-survival-in-patients-with-head-and-neck-cancers/

From https://christinowlin.blogspot.com/2019/11/study-checkpoint-inhibitor-prolongs.html

from
https://christinowlin.wordpress.com/2019/11/01/study-checkpoint-inhibitor-prolongs-survival-in-patients-with-head-and-neck-cancers/